FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034173888> ?p ?o ?g. }

• W2034173888 endingPage "876" @default.
• W2034173888 startingPage "871" @default.
• W2034173888 abstract "Background: There are still no definite treatments for refractory Kawasaki disease (KD). In this pilot study, we evaluated the use of cyclosporin A (CyA) treatment in patients with refractory KD. Methods: We prospectively collected clinical data of CyA treatment (4–8 mg/kg/d, oral administration) for refractory KD patients using the same protocol among several hospitals. Refractory KD is defined as the persistence or recurrence of fever (37.5°C or more of an axillary temperature) at the end of the second intravenous immunoglobulin (2 g/kg) following the initial one. Results: Subjects were enrolled out of 329 KD patients who were admitted to our 8 hospitals between January 2008 and June 2010. Among a total of 28 patients of refractory KD treated with CyA, 18 (64.3%) responded promptly to be afebrile within 3 days and had decreased C-reactive protein levels, the other 4 became afebrile within 4 to 5 days. However, 6 patients (21.4%) failed to become afebrile within 5 days after the start of CyA and/or high fever returned after becoming afebrile within 5 days. Although hyperkalemia developed in 9 patients at 3 to 7 days after the start of CyA treatment, there were no serious adverse effects such as arrhythmias. Four patients (1.2%), 2 before and the other 2 after the start of CyA treatment, developed coronary arterial lesions. Conclusion: CyA treatment is considered safe and well tolerated, and a promising option for patients with refractory KD. Further investigations will be needed to clarify optimal dose, safety, and timing of CyA treatment." @default.
• W2034173888 created "2016-06-24" @default.
• W2034173888 creator A5001134032 @default.
• W2034173888 creator A5006577208 @default.
• W2034173888 creator A5008714666 @default.
• W2034173888 creator A5014223853 @default.
• W2034173888 creator A5015423184 @default.
• W2034173888 creator A5018602875 @default.
• W2034173888 creator A5032370478 @default.
• W2034173888 creator A5038095725 @default.
• W2034173888 creator A5047353049 @default.
• W2034173888 creator A5049261350 @default.
• W2034173888 creator A5051462688 @default.
• W2034173888 creator A5051496751 @default.
• W2034173888 creator A5067618384 @default.
• W2034173888 creator A5072467149 @default.
• W2034173888 creator A5076492463 @default.
• W2034173888 creator A5078030250 @default.
• W2034173888 creator A5085246285 @default.
• W2034173888 creator A5090297788 @default.
• W2034173888 date "2011-10-01" @default.
• W2034173888 modified "2023-10-18" @default.
• W2034173888 title "Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin" @default.
• W2034173888 cites W1595138652 @default.
• W2034173888 cites W1596672215 @default.
• W2034173888 cites W1963598954 @default.
• W2034173888 cites W1965107349 @default.
• W2034173888 cites W1970451350 @default.
• W2034173888 cites W1973811181 @default.
• W2034173888 cites W1976197580 @default.
• W2034173888 cites W1983883436 @default.
• W2034173888 cites W1998962567 @default.
• W2034173888 cites W2000403297 @default.
• W2034173888 cites W2011736783 @default.
• W2034173888 cites W2018040903 @default.
• W2034173888 cites W2020009342 @default.
• W2034173888 cites W2023857457 @default.
• W2034173888 cites W2034604374 @default.
• W2034173888 cites W2045257748 @default.
• W2034173888 cites W2046639610 @default.
• W2034173888 cites W2052468770 @default.
• W2034173888 cites W2063554347 @default.
• W2034173888 cites W2083485009 @default.
• W2034173888 cites W2126257739 @default.
• W2034173888 cites W2134243096 @default.
• W2034173888 cites W2134773895 @default.
• W2034173888 cites W2315160100 @default.
• W2034173888 cites W2887742733 @default.
• W2034173888 cites W4231595354 @default.
• W2034173888 doi "https://doi.org/10.1097/inf.0b013e318220c3cf" @default.
• W2034173888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21587094" @default.
• W2034173888 hasPublicationYear "2011" @default.
• W2034173888 type Work @default.
• W2034173888 sameAs 2034173888 @default.
• W2034173888 citedByCount "116" @default.
• W2034173888 countsByYear W20341738882012 @default.
• W2034173888 countsByYear W20341738882013 @default.
• W2034173888 countsByYear W20341738882014 @default.
• W2034173888 countsByYear W20341738882015 @default.
• W2034173888 countsByYear W20341738882016 @default.
• W2034173888 countsByYear W20341738882017 @default.
• W2034173888 countsByYear W20341738882018 @default.
• W2034173888 countsByYear W20341738882019 @default.
• W2034173888 countsByYear W20341738882020 @default.
• W2034173888 countsByYear W20341738882021 @default.
• W2034173888 countsByYear W20341738882022 @default.
• W2034173888 countsByYear W20341738882023 @default.
• W2034173888 crossrefType "journal-article" @default.
• W2034173888 hasAuthorship W2034173888A5001134032 @default.
• W2034173888 hasAuthorship W2034173888A5006577208 @default.
• W2034173888 hasAuthorship W2034173888A5008714666 @default.
• W2034173888 hasAuthorship W2034173888A5014223853 @default.
• W2034173888 hasAuthorship W2034173888A5015423184 @default.
• W2034173888 hasAuthorship W2034173888A5018602875 @default.
• W2034173888 hasAuthorship W2034173888A5032370478 @default.
• W2034173888 hasAuthorship W2034173888A5038095725 @default.
• W2034173888 hasAuthorship W2034173888A5047353049 @default.
• W2034173888 hasAuthorship W2034173888A5049261350 @default.
• W2034173888 hasAuthorship W2034173888A5051462688 @default.
• W2034173888 hasAuthorship W2034173888A5051496751 @default.
• W2034173888 hasAuthorship W2034173888A5067618384 @default.
• W2034173888 hasAuthorship W2034173888A5072467149 @default.
• W2034173888 hasAuthorship W2034173888A5076492463 @default.
• W2034173888 hasAuthorship W2034173888A5078030250 @default.
• W2034173888 hasAuthorship W2034173888A5085246285 @default.
• W2034173888 hasAuthorship W2034173888A5090297788 @default.
• W2034173888 hasConcept C121332964 @default.
• W2034173888 hasConcept C126322002 @default.
• W2034173888 hasConcept C141071460 @default.
• W2034173888 hasConcept C142424586 @default.
• W2034173888 hasConcept C159654299 @default.
• W2034173888 hasConcept C197934379 @default.
• W2034173888 hasConcept C203014093 @default.
• W2034173888 hasConcept C2776820930 @default.
• W2034173888 hasConcept C2780243291 @default.
• W2034173888 hasConcept C2781423770 @default.
• W2034173888 hasConcept C71924100 @default.
• W2034173888 hasConcept C87355193 @default.

• next